US Latuda Sales Might Fall Short as Lawsuits Weigh: Sumitomo Dainippon Chief

Sumitomo Dainippon Pharma President Hiroshi Nomura Sumitomo Dainippon Pharma’s bread-and-butter atypical antipsychotic Latuda (lurasidone) might fail to reach its target sales in North America due to the impact of patent suits involving the drug in the US, President Hiroshi Nomura...read more